Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02372006 · ClinicalTrials.gov registry record · Phase 1
Trial of Afatinib in Pediatric Tumours
A Phase 1 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT02372006 is a Phase 1 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 56 participants.
The verdict
NCT02372006, a Phase 1 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
Open-label, dose escalation, monotherapy, basket trial with biomarker specific MTD expansion cohort/Phase II part. The trial will consist of 2 parts: 1. Dose finding part to determine the MTD 2. Biomarker specific MTD expansion cohort/Phase II part to assess clinical anti-tumour activity in included tumour types
Interventions
- DRUG afatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2015-04-29 |
| Est. Completion | 2020-08-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02372006
The ClinicalTrials.gov registry entry for NCT02372006 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which afatinib is the first listed.
NCT02372006 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02372006 about?
NCT02372006 is a clinical study titled "Trial of Afatinib in Pediatric Tumours". Open-label, dose escalation, monotherapy, basket trial with biomarker specific MTD expansion cohort/Phase II part. The trial will consist of 2 parts: 1. Dose finding part to determine the MTD 2. Biomarker specific MTD expansion cohort/Phase II part to assess clinical anti-tumour activity in includ...
What is the current status of trial NCT02372006?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2015-04-29. Estimated completion is 2020-08-05.
What interventions are being tested in trial NCT02372006?
The interventions under investigation include: afatinib (DRUG).
Who is sponsoring clinical trial NCT02372006?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.